28Sep/13

Halozyme earns $10 million milestone payment from Roche for launch of … – pharmabiz.com

Halozyme earns $10 million milestone payment from Roche for launch of
pharmabiz.com
In February 2011, Roche began a phase III registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) and submitted a line extension 

and more »